[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362513-105":59,"doc-detail-362513-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","sex-differences-in-cancer-immunotherapyclinical-evidence-and-mechanisms-with-a-focus-on-nsclc","Sex Differences in Cancer Immunotherapy—Clinical Evidence and Mechanisms With a Focus on NSCLC","","Accumulating evidence indicates subtle yet meaningful immune differences between men and women, influencing cancer development, tumor microenvironment (TME) composition, and outcomes from immunotherapies, including adverse events. Clinical trials show that mono-immunotherapies can yield greater benefit in male patients than female patients, particularly in non-small cell lung cancer (NSCLC) and melanoma, while females may benefit more from chemo-immunotherapies. Findings in human and animal models regarding sex-specific TME composition are partly divergent, driven by hormones and sex-chromosome linked genes but confounded by lifestyle factors. Key knowledge gaps persist on optimizing responses for each sex.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/sex-differences-in-cancer-immunotherapyclinical-evidence-and-mechanisms-with-a-focus-on-nsclc/362513/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/sex-differences-in-cancer-immunotherapyclinical-evidence-and-mechanisms-with-a-focus-on-nsclc/362513.png","ImageObject",300,407,{"name":92,"@type":93},"WPS_1786070896","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What are the reported effects of sex differences on cancer immunotherapy outcomes?","Question",{"text":112,"@type":113},"The document states that immune differences between men and women can affect cancer development, tumor microenvironment composition, and responses to immunotherapies, including adverse events.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do clinical trial outcomes differ between mono-immunotherapy and chemo-immunotherapy by sex?",{"text":117,"@type":113},"Several trials suggest greater benefit from mono-immunotherapies for male patients than for female patients, especially in NSCLC and melanoma, whereas female patients might benefit more from chemo-immunotherapies.",{"name":119,"@type":110,"acceptedAnswer":120},"What factors are proposed to drive observed sex differences in cancer and the tumor microenvironment?",{"text":121,"@type":113},"Hormone levels (especially testosterone and estrogen) and sex-chromosome associated genes are suggested drivers, while results are often confounded by external influences such as smoking behavior, diet, and UV exposure.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362513,1790975396,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549768072016,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Immunological Reviews  \nINVITED REVIEW  OPEN ACCESS   \nSex Differences in Cancer Immunotherapy—Clinical Evidence and Mechanisms With a Focus on NSCLC  \nEva Krieghoff-Henning1,2,3,4,5 | Balagopal Pai1,2,3 | Maike Collienne1,2,3 | Isabel Ben-Batalla2,6  | Sonja Loges1,2,3,7  \n1Department of Personalized Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany | 2Division of Personalized Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany | 3DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany | 4Division of Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany | 5National Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ and Heidelberg University Hospital, Heidelberg, Germany | 6Department of Physiology, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Santiago de Compostela, Spain | 7German Center for Lung Research (DZL), German Cancer Consortium (DKTK), Heidelberg, Germany  \nCorrespondence: Isabel Ben-Batalla ([misabel.ben@usc.es](misabel.ben@usc.es)) | Sonja Loges (sonja.loges@medma.uni-heidelberg.de)  \nReceived: 5 December 2025 | Revised: 22 January 2026 | Accepted: 24 January 2026  \nKeywords: immune checkpoint inhibitor | immunotherapy | non-small cell lung cancer/NSCLC | sex differences | testosterone | tumor microenvironment/ TME  \nABSTRACT  \nAccumulating evidence suggests that the immune system shows subtle but relevant differences between men and women. These differences may have an impact on cancer development and TME composition as well as responses to and adverse events elicited by immunotherapies. Several, albeit not all, clinical trials indicate a greater benefit from mono-immunotherapies over chemotherapies for male patients than for female patients, especially in non-small cell lung cancer and melanoma. Vice versa, female patients might benefit more from chemo-immunotherapies. In human as well as animal models, sex differences in cancer microenvironment composition were described, with partially divergent results. Sex-specific factors such as the levels of hormones, in particular testosterone and estrogen, or X-or Y-chromosome associated genes are likely to drive the observed differences, but are often confounded by external influences such as smoking behavior, diet, or UV exposure. Therefore, large clinical and mechanistic knowledge gaps remain regarding the influence of sex on cancer immunotherapies and strategies to optimize response in either sex. More clinical as well as experimental research in this field is required to close these knowledge gaps, and clinical trials should include large enough groups of male and/or female patients to allow robust sex-specific analyses.  \n1 | Main  \nAlthough it may appear obvious that the known physiological differences that exist between men and women may also influence health overall, disease susceptibility and treatment outcomes, the field of “gender medicine” is still in its relative infancy, particularly with respect to cancer that is not exclusive to one sex. In this review, we revisit the available data on potential  \ndifferences between the sexes with a focus on non-small cell lung cancer (NSCLC) and immune checkpoint inhibitor therapy, both from a clinical and a more mechanistic basic research perspective. In line with common practice, we refer to patients'sex when we refer to “intrinsic”, physiologic, sex-chromosomally driven factors that differentiate between biological male and female individuals, while we refer to patients' gender when nonbiological factors such as lifestyle differences are considered.  \n\n| Eva Krieghoff-Henning, Balagopal Pai, Isabel Ben-Batalla and Sonja Loges contributed equally. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any ","cbCaijtB2bFRrwVW","https://ap.wps.com/l/cbCaijtB2bFRrwVW","pdf",1895837,28,"English","# Abstract\n## Sex-Specific Differences in Cancer Incidence\n## Main","[{\"question\":\"What are the reported effects of sex differences on cancer immunotherapy outcomes?\",\"answer\":\"The document states that immune differences between men and women can affect cancer development, tumor microenvironment composition, and responses to immunotherapies, including adverse events.\"},{\"question\":\"How do clinical trial outcomes differ between mono-immunotherapy and chemo-immunotherapy by sex?\",\"answer\":\"Several trials suggest greater benefit from mono-immunotherapies for male patients than for female patients, especially in NSCLC and melanoma, whereas female patients might benefit more from chemo-immunotherapies.\"},{\"question\":\"What factors are proposed to drive observed sex differences in cancer and the tumor microenvironment?\",\"answer\":\"Hormone levels (especially testosterone and estrogen) and sex-chromosome associated genes are suggested drivers, while results are often confounded by external influences such as smoking behavior, diet, and UV exposure.\"}]","Sex Differences in Cancer Immunotherapy—Clinical Evidence and Mechanisms With a Focus on NSCLC | PDF",1790148043,71,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac4216d46536947870de2732ee724065.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f317d3a865de077c27e8b8f3021bf779.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d6a7412e25250eefbb1b8fb06dd02f3f.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee4857877e7000720d9bf5ce46538f5c.webp",980,1287]